MEDI5083 + durvalumab + docetaxel

MEDI5083 + durvalumab + docetaxel is an investigational combination therapy for advanced solid tumors. **MEDI5083** is a novel, hexameric recombinant human CD40 ligand (CD40L) fused to a human IgG4P Fc domain, designed as a trimerized IgG fusion protein to mimic the native ligand and activate the CD40 pathway on antigen-presenting cells. This activation bridges innate and adaptive immunity by promoting direct tumor cell apoptosis, enhancing cytotoxic T-cell responses, and stimulating immune cell activation[1][2][7]. **Durvalumab** is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby blocking its interaction with PD-1 and enabling T-cell mediated anti-tumor activity. **Docetaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis in cancer cells. The combination was studied in phase 1 clinical trials for patients with various advanced solid tumors including bladder, breast, colon, head and neck, kidney, lung, pancreas[2][6]. The development of subcutaneous MEDI5083 was discontinued due to safety concerns including high rates of injection-site reactions[6].

Other names

CD40L-Fc fusion protein (for MEDI5083)IMC-Durvalumab (for durvalumab)NSC 628503 (for docetaxel)